Study of ACE Reno, Pico Cell Matrix for kidney health
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have kidney disease (any stage from 1 to 5, not on dialysis).
- You may have early signs (microalbuminuria), more protein in your urine, or have had a kidney transplant with protein in urine.
- You can be on standard kidney medicines like ACE inhibitors, ARBs, SGLT2 inhibitors, or MRAs.
- You must not have had a kidney transplant within the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This is a flexible research study for adults with advanced kidney disease. Depending on which part of the study you qualify for, you may test new treatments designed to slow kidney disease, reduce complications, or improve your health while on dialysis or after transplant.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
This trial studies whether an ACE inhibitor (a blood-pressure/kidney-protecting medicine) is safe and effective for adults with Alport syndrome caused by certain COL4A3/COL4A4/COL4A5 gene variants. It aims to see if treatment can help protect kidney function in people who currently have signs like blood or small amounts of protein in the urine.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.